Advisor ADC Drug-Linker Synthetic Process Development at Eli Lilly and Company

Indianapolis, Indiana, United States

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

Fluent knowledge in synthetic organic chemistry methods, technologies, and techniques
Ability to design and develop robust synthetic manufacturing processes for clinical manufacturing campaigns
Solid understanding in unit operation design, process modeling, process equipment selection, and scale-up methodologies
Skillset and knowledge to grow team capabilities, research facilities, and infrastructure for highly-potent and/or cytotoxic ADC drug-linkers
Ability to synthesize complex payloads and drug-linkers for preclinical tox studies
Ability to provide technical leadership in scale-up and demonstration of new chemical processes
Ability to design experimental laboratory plans for route and process design, definition, optimization, and technology transfer
Ability to generate data for regulatory filings and address key CMC regulatory questions
Ability to engage the external chemistry community through presentations and publications

Responsibilities

Synthesize complex payloads and drug-linkers for preclinical tox studies and collaborate across internal Lilly networks to deliver material and information
Work closely with early phase Discovery and Toxicology groups to support new and emerging assets via synthetic material supply
Provide technical leadership in the scale-up and demonstration of new chemical processes in development scale equipment
Collaborate with internal and external manufacturing partners to develop robust chemical processes amenable to efficient drug substance manufacturing
Design experimental laboratory plans in support of route and process design, definition, optimization, and technology transfer objectives
Support generating data to be used in regulatory filings and address key CMC regulatory questions that enable clinical studies
Engage the external chemistry community through presentations and publications
Collaborate with other Lilly chemists, analytical chemists, bioconjugation scientists, engineers, and CMC project managers

Skills

Synthetic Chemistry

Drug-Linker Synthesis

ADC Development

Small Molecule Chemistry

Process Development

Bioconjugates

Monoclonal Antibodies

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters

1876Year Founded

$1,180.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.

Potential construction delays in Indiana could affect GLP-1 drug production timelines.

Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.

Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.

FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.

Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.

Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI

Try Jobo Free